Literature DB >> 15383757

Surgery of gastroesophageal reflux disease: a competitive or complementary procedure?

Lars Lundell1.   

Abstract

The management of chronic gastroesophageal reflux disease (GERD) has both been simplified and immensely improved by the development of modern medical therapies. These are built entirely on the concept of profound acid inhibition, which is very successful in a substantial proportion of GERD patients. Despite the efficacy of proton pump inhibitors (PPIs) some failures are unavoidable, and some patients experience incomplete control of major GERD symptoms on ordinary dosing of PPIs. Although the safety profile of PPIs is very reassuring, some people express some concern about the safety of drug treatment extending beyond 10 years especially when alternative therapeutic strategies are available. Some patients complain of alleged respiratory complications to severe reflux, and in those situations as well as in cases with e.g. Barrett's esophagus, a complete control of reflux also incorporating the duodenal components in the refluxate may be warranted. In all those situations antireflux surgery can be considered indicated for the treatment of chronic GERD and thus be looked upon as complementary to medical therapy. Furthermore, some patients who have their GERD symptoms under control on PPIs still want to have an operation to avoid dependency on drugs. Hence in none of these clinical situations does antireflux surgery play a competitive role in relation to medical therapy. However, in the very few randomized clinical trials in which a head-to-head comparison has been completed between medical and surgical therapy, the latter has been found to be somewhat more effective in terms of reflux control. The other side of the coin is that antireflux surgery has some side effects that signify the importance of this surgery being performed in specialized centers. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383757     DOI: 10.1159/000080315

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  6 in total

1.  Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.

Authors:  Bart P L Witteman; Jose M Conchillo; Nicolaas F Rinsma; Bark Betzel; Andrea Peeters; Ger H Koek; Laurents P S Stassen; Nicole D Bouvy
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

2.  Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX.

Authors:  Guy-Bernard Cadière; Nathalie Van Sante; Jaime E Graves; Anna K Gawlicka; Amin Rajan
Journal:  Surg Endosc       Date:  2009-03-14       Impact factor: 4.584

3.  Nissen versus Toupet fundoplication: results of a randomized and multicenter trial.

Authors:  E Guérin; K Bétroune; J Closset; A Mehdi; J C Lefèbvre; J J Houben; M Gelin; P Vaneukem; I El Nakadi
Journal:  Surg Endosc       Date:  2007-11       Impact factor: 4.584

Review 4.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

5.  Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice.

Authors:  Bart P L Witteman; Rob Strijkers; Eva de Vries; Liza Toemen; José M Conchillo; Wim Hameeteman; Pieter C Dagnelie; Ger H Koek; Nicole D Bouvy
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

6.  Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study.

Authors:  Guy-Bernard Cadière; Michel Buset; Vinciane Muls; Amin Rajan; Thomas Rösch; Alexander J Eckardt; Joseph Weerts; Boris Bastens; Guido Costamagna; Michele Marchese; Hubert Louis; Fazia Mana; Filip Sermon; Anna K Gawlicka; Michael A Daniel; Jacques Devière
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.